{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:55:40Z","timestamp":1790963740722,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.eururo.2020.02.012","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:58:27Z","timestamp":1583283507000},"page":"387-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non\u2013muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6980-4777","authenticated-orcid":false,"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.02.012_bib0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.02.012_bib0010","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0015","first-page":"29","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.eururo.2020.02.012_bib0020","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry","first-page":"1","author":"Administration","year":"2018"},{"key":"10.1016\/j.eururo.2020.02.012_bib0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.eururo.2020.02.012_bib0030","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette\u2010Guerin after initial bacille Calmette\u2010Guerin failure in non\u2010muscle\u2010invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.02.012_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000090870","article-title":"Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study","volume":"76","author":"Gacci","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.02.012_bib0040","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0045","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0050","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0055","year":"2018"},{"key":"10.1016\/j.eururo.2020.02.012_bib0060","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0065","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","article-title":"Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon alpha2b formulated in Syn3 for failures of bacillus Calmette-Guerin (BCG) therapy in nonmuscle invasive bladder cancer","volume":"23","author":"Navai","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0070","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2020.02.012_bib0075","first-page":"e999","article-title":"LBA-18 Preliminary phase 2 clinical results of IL-15R\u03b1FC superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients demonstrates 82% CR of carcinoma in situ (CIS)","volume":"201","author":"Chamie","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","article-title":"Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin","volume":"51","author":"Sarosdy","year":"1998","journal-title":"Urology"},{"issue":"7_suppl","key":"10.1016\/j.eururo.2020.02.012_bib0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000089164","article-title":"Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.02.012_bib0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0100","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0105","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0110","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2020.02.012_bib0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial","volume":"21","author":"Perdona","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.eururo.2020.02.012_bib0120","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single arm phase I\/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2_suppl","key":"10.1016\/j.eururo.2020.02.012_bib0135","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/jco.2016.34.2_suppl.451","article-title":"Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC)","volume":"34","author":"Sonpavde","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.eururo.2020.02.012_bib0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2020.02.012_bib0150","first-page":"e229","article-title":"PD13-10 Oncological outcomes of BCG unresponsive non-muscle invasive bladder cancer patients treated with postoperative chemohyperthermia: a multicentre European retrospective analysis","volume":"201","author":"Tan Wei","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0155","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"Electromotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \"BCG failure\" non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2020.02.012_bib0160","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2020.02.012_bib0165","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2017.35.6_suppl.313","article-title":"A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder","volume":"35","author":"DeCastro","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0175","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2020.02.012_bib0185","first-page":"e312","article-title":"PD18-04 A phase 1 safety study of Oncofid-P-B administered for 12 consecutive weeks in BCG unresponsive\/intolerant patients with bladder carcinoma in situ (CIS): preliminary results","volume":"201","author":"Hurle","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0190","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0200","year":"2009"},{"key":"10.1016\/j.eururo.2020.02.012_bib0205","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network trial HCRN 12-157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2020.02.012_bib0210","first-page":"313","article-title":"A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients","volume":"4","author":"Kowalski","year":"2010","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.eururo.2020.02.012_bib0215","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0220","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1016\/j.juro.2018.03.099","article-title":"LBA27 Phase 3 study of vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results","volume":"199","author":"Dickstein","year":"2018","journal-title":"J Urol"},{"issue":"7_suppl","key":"10.1016\/j.eururo.2020.02.012_bib0225","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/jco.2011.29.7_suppl.262","article-title":"Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder","volume":"29","author":"Garcia","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0230","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0235","first-page":"39","article-title":"Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder","volume":"160","author":"Nseyo","year":"1998","journal-title":"Bladder Photofrin Study Group. J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2 Pt 1","key":"10.1016\/j.eururo.2020.02.012_bib0245","first-page":"494","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/BLC-170118","article-title":"Once BCG unresponsive, always BCG unresponsive: an open letter to the FDA to enhance recruitment into clinical trials in bladder cancer","volume":"3","author":"Kamat","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2020.02.012_bib0260","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-5347(01)61605-7","article-title":"Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent","volume":"161","author":"Schneeweiss","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0265","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0270","unstructured":"Dinney C, editor. Phase 3 trial of rAd-IFNa\/Syn3 for BCG unresponsive NMIBC. Society of Urologic Oncology Annual Meeting; 12\/5\/2019; Washington, DC."},{"key":"10.1016\/j.eururo.2020.02.012_bib0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0280","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0285","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on bacillus Calmette-Guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0290","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.02.012_bib0300","author":"US FDA"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820301184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820301184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:59Z","timestamp":1759583219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820301184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0302283820301184"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.02.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non\u2013muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Gu\u00e9rin","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}